Wits Vida- Chris Hani Baragwanath Hospital
Welcome,         Profile    Billing    Logout  
 0 Trials 
2 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Koen, Anthonet L
NCT05468736: Study to Evaluate Safety and Immunogenicity of COVID-19 Vaccine in Children 6 Months to < 12 Years

Active, not recruiting
2/3
3600
Europe, US, RoW
Biological/Vaccine: SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period), NVX-CoV2373, SARS-CoV-2 rS/Matrix-M1 Adjuvant (Open Label Crossover Vaccination period), SARS-CoV-2 rS/Matrix-M1 Adjuvant (Booster Vaccination), Placebo, Sodium chloride 0.9% (BP, sterile)
Novavax
COVID-19
11/23
09/25
NCT05370040: THEMBA II T-Cell Vaccine: Vaccination With saRNA COVID-19 Vaccines

Terminated
1/2
60
RoW
AAHI-SC2 Vaccine, AAHI-SC3 Vaccine, EUA or approved vaccine
ImmunityBio, Inc.
COVID-19
03/24
03/24

Download Options